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Abstract
Introduction: The purpose of this research was to study the influence of cigarette smoking and alcohol
consumption on immune response to heptavalent pneumococcal conjugate vaccine, immunoglobulin levels (Ig)
and markers of systemic inflammation in patients with rheumatoid arthritis (RA) or spondylarthropathy (SpA).
Methods: In total, 505 patients were vaccinated. Six pre-specified groups were enrolled: RA on methotrexate (MTX)
treatment in some cases other disease-modifying antirheumatic drugs (DMARDs) (I); RA on anti-tumour necrosis
factor (TNF) as monotherapy (II); RA on anti-TNF+MTX+ possibly other DMARDs (III); SpA on anti-TNF as monotherapy
(IV); SpA on anti-TNF+MTX+ possibly other DMARDs (V); and SpA on nonsteroidal anti-inflammatory drugs (NSAIDs)
and/or analgesics (VI). Smoking (pack-years) and alcohol consumption (g/week) were calculated from patient
questionnaires. Ig, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were determined at vaccination.
IgG antibodies against serotypes 23F and 6B were measured at vaccination and after four to six weeks using standard
ELISA. Immune response (ratio between post- and pre-vaccination antibodies; immune response (IR)) and positive
immune response (≥2-fold increase in pre-vaccination antibodies; posIR) were calculated.
Results: Eighty-eight patients (17.4%) were current smokers. Smokers had higher CRP and ESR, lower IgG and
lower IR for both serotypes (P between 0.012 and 0.045). RA patients on MTX who smoked ≥1pack-year had lower
posIR for both serotypes (P = 0.021; OR 0.29; CI 0.1 to 0.7) compared to never-smokers. Alcohol consumption was
associated with lower CRP (P = 0.05) and ESR (P = 0.003) but did not influence IR or Ig levels.
Conclusion: Smoking predicted impaired immune response to pneumococcal conjugate vaccine in RA patients on
MTX. Smokers with arthritis had higher inflammatory markers and lower IgG regardless of diagnosis and treatment.
Low to moderate alcohol consumption was related to lower levels of inflammation markers but had no impact on
immune response.
Trial registration: EudraCT EU 2007-006539-29 and NCT00828997
Introduction
Pneumococcal vaccination is recommended to all adults
age 65 or older and subjects younger than 65 years with
chronic and immunosuppressing conditions. In addition,
adult cigarette smokers and immunocompetent persons
with underlying conditions, such as alcoholism, should
receive this vaccine regardless of age [1]. Cigarette
smoking was found to be an independent risk factor for
invasive pneumococcal disease in immunocompetent
adults younger than 65 years and the risk increased with
increased smoking pack-years [2]. It has also been
shown that interaction between smoking and certain
genetic factors increases risk of rheumatoid arthritis
(RA) [3]. Investigation of immune and inflammatory
functions in cigarette smokers including levels of immu-
noglobulins (Ig) and antibody response after vaccination
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have given conflicting results [4-9]. Excess alcohol is
shown to suppress a wide range of immune responses
predisposing the host to various infections, and in parti-
cular pulmonary ones [9,10]. On the other hand, moder-
ate consumption of alcoholic beverages may enhance
immune response [11,12].
The majority of patients with inflammatory arthritis,
such as RA or spondylarthropathy (SpA), receiving
immunosuppressive treatments with disease-modifying
antirheumatic drugs (DMARDs), biologic remedies or
long-term systemic steroids are at an increased risk for
invasive pneumococcal disease and, therefore, a target
group for pneumococcal vaccination. We have demon-
strated a diminished antibody response following pneu-
mococcal vaccination (both 23-valent polysaccharide and
7-valent conjugate) in arthritis patients treated with
methotrexate (MTX) compared to those receiving anti-
tumour necrosis factor (TNF) agents [13,14] and SpA
patients not taking any immunosuppressive drugs [14].
The aim of this study was to examine the impact of
cigarette smoking and alcohol drinking habits on markers
of systemic inflammation, such as C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR), total
serum Ig levels and immune response following pneumo-
coccal vaccination using 7-valent pneumococcal conju-
gate vaccine in patients with RA and SpA treated with
different anti-inflammatory remedies.
Materials and methods
In all, 505 patients with RA (N = 253) and SpA includ-
ing psoriatic arthritis (N = 252) receiving different anti-
inflammatory treatments were vaccinated with a single
dose of 7-valent pneumococcal conjugate vaccine
(Prevenar®, Whyeth Pharmaceutica, Collegeville, PA,
USA) intramuscularly as previously described [14]. All
patients were stratified into six pre-specified groups
based on diagnosis and treatment. These were: I RA
patients on MTX+ in some cases other disease-modify-
ing antirheumatic drugs (DMARDs) (n = 85); II RA on
anti-TNF as monotherapy (n = 79); III RA on anti-TNF
+MTX+ possibly other DMARDs (n = 89); IV SpA
patients on anti-TNF drugs as monotherapy (n = 83); V
SpA on anti-TNF drugs+MTX (n = 83) and VI SpA
patients on NSAIDs and/or analgesics (n = 86). No
changes in anti-rheumatic treatment within four weeks
prior to and up to six weeks following vaccination were
allowed.
Measurement of IgG, IgA and IgM serum concentra-
tions by nephelometry using Beckman-Coulter reagents
on the Immage 800 instrument (Beckman Coulter, Brea,
CA, USA) and determination of CRP and ESR were per-
formed at vaccination.
Serotype specific IgG against pneumococcal polysac-
charide serotypes 23F and 6B were measured in sera
using standard ELISA as described previously [14,15].
Immune response (IR) was defined as the ratio between
post- and pre-vaccination antibody levels. GMC (geo-
metric mean concentrations of antibody responses) were
calculated. A positive immune response (posIR) was
defined as IR ≥2.
All patients were asked to complete a questionnaire
regarding smoking and alcohol drinking habits. Original
data on smoking status were available for about 80% of
participants in the study. Missing data were retrieved
through a telephone call from one researcher (CR) to all
subjects initially not responding to the questionnaire.
Thereby, data on smoking status were available for 502 of
505 study patients. Regarding smoking status, the follow-
ing groups were defined: current smokers, non-smokers,
ex-smokers and ever-smokers. Ever-smokers denote sub-
jects who had smoked for some period of their life or still
smoke (ex-smokers + current smokers). Cumulative expo-
sure to cigarette smoking at vaccination was calculated as
smoking pack-years. A pack-year corresponds to 20 cigar-
ettes smoked daily for one year. Alcohol consumption was
calculated from self-reported data on usage of alcoholic
beverages. The number of each alcoholic beverage/week
multiplied by average alcohol content in each portion of a
drink corresponded to alcohol intake in grams/week [16].
The total alcohol intake/week was calculated as a sum of
alcohol content from all alcoholic beverages consumed
per week. Data on current alcohol consumption were
missing in 24 patients (4.8%). Low to moderate alcohol
consumption was defined as total alcohol intake <30 g/day
[17].
Ethical considerations
Consecutive patients fulfilling inclusion criteria were
invited to participate in the study. Oral and written infor-
mation was provided to all subjects who were invited to
participate, and written informed consent was obtained
from each participant before enrolment. Ethical approval
for the vaccination was obtained from the Ethical Review
Board at Lund University (file number 97/2007). The
study was conducted as an investigator driven clinical trial
(EudraCT EU 2007-006539-29 and NCT00828997) and
approved by the Swedish medical products agency (MPA;
Läkemedelsverket; file number 151: 2007/88047).
Statistical analyses
Comparisons were done using Chi-squared, Mann-Whit-
ney U test and independent sample T-test and pair sample
T-test, when appropriate. Correlations were calculated by
Spearman´s correlation coefficient. Univariate analysis of
variance (ANCOVA) was used to study the impact of
smoking and alcohol consumption on CRP, ESR, Ig levels,
pre- and post-vaccination antibody levels for each serotype
and IR. Adjustment for multiple comparisons was
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performed using the Bonferroni corrections method.
Effects of smoking and drinking habits on posIR were ana-
lysed using binary logistic regression model. A P-value of
<0.05 was considered significant.
Results
Baseline characteristics
Demographic characteristics, smoking and alcohol con-
sumption status, immune responses, levels of inflamma-
tory markers, and Ig levels in the entire study population
and in the different treatment groups are summarised in
the Table 1.
At vaccination, RA patients on anti-TNF+MTX had
significantly lower CRP compared to the other two RA
treatment groups (P = 0.019 and P = 0.009, compared to
group I and group II, respectively). IgG, IgA and IgM
levels were significantly lower in RA patients on MTX
(group I) compared to RA patients on anti-TNF as
monotherapy or RA on anti-TNF +MTX (P between
0.032 and <0.001; independent sample T-test).
SpA patients on anti-TNF+MTX had lower CRP com-
pared to the other SpA treatment groups (P = 0.001 and
<0.001, compared to group IV and VI, respectively). No
statistically significant differences of Ig levels were seen
among groups of patients with SpA.
The effect of cigarette smoking in the total study
population
Of 505 patients enrolled in the study, 290 (57.4%) smoked
for some period of their life or still smoke (ever smokers).
The total smoking load expressed in number of smoking
pack-years (mean; SD; range) was 19.3 (14; 0 to 65). In
total, 212 patients (42%) had never smoked and no data
on smoking status were available in 3 patients (0.6%). Two
hundred, two patients (40%) had previously smoked but
quit smoking before the study entry (ex-smokers). Mean
(SD; range) of smoking pack-years in this group was 16.6
(13; 1 to 65).
In all, 88 patients (17.4%) of the population studied were
current smokers at the time of vaccination. Mean (SD;
range) number of cigarettes per day was 10.1 (6.4; 0 to 30).
Mean (SD; range) number of smoking pack-years was 24.5
(13; 0 to 57). Of all current smokers, 64 individuals
(72.7%) were females and 24 (27.3%) males (P = 0.029).
Differences in measured markers of inflammation, IgG
levels and GMC of immune responses for each serotype
between non-smokers, ex-smokers and current smokers
are given in Table 2.
Current smokers had significantly higher CRP and ESR
compared to non-smokers (Table 2). Number of pack-
years of smoking was significantly correlated with both
CRP (Spearman’s rho = 0.152; P = 0.001) and ESR (Spear-
man’s rho = 0.159, P = 0.001). The findings persisted in
univariate ANCOVA with age, gender, number of tender
and swollen joints in 28-joint count index, MTX, anti-
TNF treatment, prednisolone and alcohol consumption
included in the analysis. Smoking had a significant impact
on both CRP (P = 0.008) and ESR (P = 0.037).
At the time of vaccination, current smokers had
significantly lower total IgG levels compared to non-
smokers but IgA and IgM levels did not differ signifi-
cantly. Both daily cigarette number at the time of vacci-
nation and number of pack-years were inversely
correlated with IgG levels (Spearman’s rho -0.132 (P =
0.003) and -0.130 (P = 0.006), respectively). These find-
ings were confirmed by ANCOVA with age, gender,
DAS, MTX, anti-TNF prednisolone treatment and alco-
hol consumption as covariates.
GMC of antibody responses, that is, the ratio between
post- and pre-vaccination antibody levels, were signifi-
cantly higher in non-smokers for both serotypes (Table 2).
This was not corroborated by univariate ANCOVA after
adjustment for demographic, disease and treatment char-
acteristics. Neither did smoking status predict a posIR for
each serotype separately nor both 23F and 6B together.
Number of pack-years did not correlate with antibody
levels or IR and did not predict a posIR for either serotype
or both serotypes together.
Effect of cigarette smoking within different diagnostic
and treatment groups
The percentage of current smokers in different treat-
ments groups were: 19, 18, 19, 12, 24 and 12% (Table 1).
The proportion of current smokers did not differ signifi-
cantly between the groups of patients with RA. Among
patients with SpA more patients on anti-TNF+MTX
were smokers (P = 0.05 and 0.04, compared to group 4
and 6, respectively).
Group I (RA on MTX)
In RA patients on MTX, current smokers had signifi-
cantly higher CRP and ESR. This was also demonstrated
using univariate ANCOVA, where age, gender, number
of tender and swollen joints in 28-joint count index were
included in the analysis (P = 0.023 for CRP and P = 0.023
for ESR). However, total IgG, IgA and IgM levels did not
differ between smokers and non-smokers in this treat-
ment group. Ever-smokers among RA patients on MTX
had a lower proportion of responders to vaccination for
both serotypes (P = 0.025; OR 0.21; 95% CI 0.05 to 0.81)
compared to never-smokers (Figure 1). Also, higher
pack-years were associated with lower posIR (P = 0.046;
OR 0.93 95% CI 0.86 to 0.99) after adjustment for age,
sex, CRP, counts of affected joints (tender joint count
(TJC) and swollen joint count (SJC)) and pre-vaccination
antibody levels (Table 3).
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Number of patients at vaccination 505 85 79 89 83 83 86
Females (%) 63 79 87 78 34 53 45
CRP g/L (mean) 6.7 8.9 9.4 5.9 2.9 5.1 7.7
ESR mm/h (mean) 21.5 28.3 28.6 24.4 11.7 15.3 ( 5 15.3 19.8
Current smokers (%) 17 19 19 18 12 24 12
Ex-smokers (%) 40 39 38 45 45 39 35
Ever-smokers (%) 57.4 56.5 57.0 65.2 55.4 60.2 44.2
Smoking pack-years; mean (SD) 19.4 (14) 22.0
(13)
21.0 (15) 20.4 (14) 16.0 (13) 19.4 (13) 16.8 (13)
Current alcohol drinking (g/week) mean (SD) 9.7 (9) 13.2
(11)
8.0 (9) 10.4 (13) 12.2 (12) 8.5 (8) 11.8 (9)
IgG at vaccination (g/L)(SD) 10.4 (2.7) 9.7 (2.5) 11.8 (3.3) 11.0 (3.3) 9.9 (1.9) 9.9 (2.2) 9.9 (2.1)
IgM at vaccination (g/L)(SD) 1.3 (0.8) 1.1 (0.6) 1.7 (1.0) 1.4 (0.7) 1.3 (0.8) 1.2 (0.7) 1.0 (0.6)
IgA at vaccination (g/L)(SD) 2.7 (1.2) 2.5 (1.0) 3.3 (1.4) 2.8 (1.2) 2.7 (1.1) 2.4 (1.1) 2.5 (1.1)
Immune response (IR) for 23F (mean) 1 3.5 2.5 3.4 2.2 4.8 3.0 6.6
Immune response (IR) 1 for 6B (mean) 2.3 1.8 2.7 1.6 3.1 1.8 3.3
Patients with protective antibody levels for both 23F and 6B 4-6
weeks after vaccination (%)(posIR) 2
32.9 21.2 36.7 15.7 50.6 20.5 47.7
1Immune response = ratio between post- and prevaccination antibody levels.
















Groups II to VI
Smoking habits had no effect on acute phase reactants,
Ig levels, pre- and post-vaccination antibody levels, IR
or posIR against pneumococcal serotypes 6B or 23F in
any of the other treatment groups.
Effect of alcohol drinking in the total study population
Of the participating 505 patients, 148 (29.3%) reported
no or sporadic alcohol consumption in very small
amounts, while 333 (65.9%) patients reported alcohol
consumption on a regular basis. Median (range) con-
sumption among patients using alcoholic beverages was
70.8 (5.3 to 758) g/week. The majority of patients parti-
cipating in the study reported low to moderate alcohol
use corresponding to ≤30 g 100% ethanol daily. Alcohol
consumption was more common in men (P <0.001).
Compared to non-drinkers, patients regularly consuming
alcohol showed lower levels of CRP and ESR (P = 0.007
Table 2 Markers of inflammation, Ig and immune response according to smoking status in total study population
Current smokers (N = 88) Non-smokers (never-smoked) (N = 212) Ex-smoker
(N = 202)
Smoking pack-years (mean; SD) 24.5 (13)* — 16.6 (13)*
CRP g/L (mean) (SD) 10.1 (25)** 5.9 (10)** 5.8 (11)**
ESR mm/hour (mean) (SD) 25.6 (22)*** 19.8 (17)*** 21.4 (19)
IgG g/L (mean) (SD) 9.9 (3) # 10.6 (2) 10.4 (3)
IgA g/L (mean) (SD) 2.6 (1) 2.7 (1) 2.7 (1)
IgM g/L (mean) (SD) 1.2 (0.6) 1.3 (0.9) 1.3 (0.7)
GMC¤ immune response 23F 2.6 ## 3.7 3.3
GMC¤ immune response 6B 1.8 ### 2.4 2.2
GMC¤ = geometric mean concentration of immune response
*P <0.001 compared to ex-smokers (independent sample T-test)
** P = 0.04 compared to non smokers (never-smoked); p = 0.045 compared to ex-smokers (independent sample T-test)
*** P = 0.023 compared to non-smokers (never-smoked); independent sample T-test
#P = 0.028 compared to non-smokers (never-smoked); independent sample T-test
## P = 0.028 compared to non-smokers (never-smoked); Mann-Whitney U test
### P = 0.0042 compared to non-smokers (never-smoked); Mann-Whitney U test
Figure 1 Responders(%) to 23F, 6B and both pneumococcal serotypes in methotrexate treated RA patients according to smoking
status. Responders i.e. patients with positive immune response defined as post-vaccination antibody levels ≥2 times pre-vaccination antibody
levels. Ever smoked i.e. previous/current smokers
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and P <0.001; T-test) also remaining after univariate
ANCOVA, including age, gender, number of tender and
swollen joints in 28-joint count index, and after adjustment
for multiple comparisons (P = 0.05 and P = 0.003, for CRP
and ESR, respectively).
However, serum Ig levels, GMC of antibody responses
or posIR were not influenced by the reported alcohol
consumption.
Effect of alcohol drinking within different diagnostic and
treatment groups
Within each treatment group, no significant differences
in CRP, ESR, Ig levels, GMC of antibody responses or
pos IR were detected among persons not consuming
alcoholic beverages compared to those drinking alcohol.
Discussion
In this study, we report the impact of patient reported
smoking and alcohol drinking habits on markers of sys-
temic inflammation (CRP and ESR), serum level of Ig and
immune response after standardised antigen challenge
(pneumococcal vaccination using heptavalent conjugate
vaccine) in patients with established RA and spondylar-
thropathy treated with different anti-inflammatory
remedies.
A main finding is that smokers in this study had higher
acute phase reactants, such as CRP and ESR, compared to
non-smokers regardless of anti-rheumatic treatment. Our
results are in accordance with some other previously pub-
lished studies reporting the impact of smoking on several
markers of systemic inflammation [8,18-20]. Patients with
RA and SpA are known to have an increased risk of cardi-
ovascular disease, probably mediated through the inflam-
matory nature of these diseases but smoking may further
increase the risk.
Another important finding is that, in the entire popula-
tion of arthritis patients participating in this study, cur-
rent smokers had lower serum levels of IgG compared
with non-smokers regardless of diagnosis or ongoing
anti-rheumatic treatment. Both higher numbers of cigar-
ettes smoked daily and total smoking load expressed as
number of pack-years were associated with lower IgG
levels. These results are in accordance with earlier
reports on 10 to 20% reduced Ig concentrations in smo-
kers [8] and more recent findings showing lower Ig con-
centrations in healthy individuals smoking for more than
10 years [5].
Total IgG, IgM and IgA levels were significantly lower in
RA patients treated with MTX compared to RA patients
treated with anti-TNF as monotherapy or anti-TNF com-
bined with MTX. The mechanisms of action of MTX are
complex and not entirely known [21] but probably include
the effect on B-cells as well. Decreased numbers and sub-
sets of memory B-cells have recently been reported in
patients with RA compared with age matched controls
[22]. Among RA patients, those with MTX treatment had
significantly lower B-cell numbers compared to RA
patients treated with anti-TNF and MTX in combination
[21,22]. We found no differences in Ig levels between SpA
treatment groups. On the other hand, patients with SpA
only treated with MTX were not included in this study
and the influence of RA on Ig levels cannot be entirely
ruled out. One may speculate that RA patients on MTX
monotherapy may have a less severe disease and thus a
more profound immunological impact of MTX on their
immune system compared to RA patients requiring addi-
tional or other remedies for disease control.
When the effects of current smoking on immune
response following pneumococcal vaccination was ana-
lysed in the entire study population, we detected signifi-
cantly lower antibody responses in current smokers.
However, these differences between smokers and non-
smokers were not seen after correcting for treatment
group and disease characteristics. Also, the results are in
contrast to a reported increased level of pneumococcal
antibodies in smokers [2]. The contrasting findings
Table 3 Impact of smoking on positive immune response forpneumococcal serotypes(23F and 6B) in RA patients on
methotrexate
B P-value Exp(B) 95% CI
Lower Upper
Smoking (pack-years) -0.07 0.046 0.93 0.86 0.99
Age (years) -0.01 0.724 0.99 0.95 1.03
Gender 0.85 0.341 2.34 0.41 13.43
CRP -0.03 0.639 0.98 0.88 1.08
SJC28* -0.09 0.502 0.91 0.69 1.20
TJC28* 0.00 1.000 1.0 0.76 1.32
Pre-vaccination antibody levels for serotype 23F -0.42 0.090 0.66 0.41 1.07
Smoking (ever) -1.58 0.025 0.21 0.05 0.81
*swollen and tender joint count in 28-joint count index
Two different logistic regression models were created analyzing smoking (pack-years) and smoking (ever) variable, respectively adjusted for the same covariates.
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reported may reflect differences in study population
since the previous study comprised a random sample of
elderly inhabitants aged 64 to 97 years probably not
treated with immunosuppressive drugs. Since very few
women enrolled in that study were smokers, only men
were included in analysis of smoking effects on antibody
response. Interestingly, compared to men, significantly
more women in our study were smokers. The higher
proportion of smokers among women in our study
could be explained by opposite trends in the smoking
behaviour between men and women recognised later in
the 20th century in the industrialised countries when
smoking became more common among women but
decreased in men [23]. A pathogenetic impact of smok-
ing on RA disease possibly with greater penetrance in
women cannot be ruled out [3]. The immunogenicity
between pneumococcal serotypes differs significantly
and since antibody response to different serotypes were
analysed in the mentioned study [4], our results cannot
be directly compared. Serotypes 23F and 6B are
reported to be associated with invasive pneumococcal
diseases in Sweden, which was the main reason for
choosing these particular two serotypes in the present
study [24]. Analyzing all seven serotypes in the vaccine
would result in a more exact and probably also more
reliable estimation of antibody responses in the study
population. However, we assume that the underlying
mechanisms responsible for effects of smoking and
drinking on antibody response would be similar in all
serotypes.
When the effect of smoking on immune response was
analysed in the separate treatment groups, both ever
smoking and number of pack-years were associated with
impaired antibody response only in RA patients on MTX
monotherapy. We have previously reported that this
group has the lowest IR and posIR following pneumococ-
cal vaccination [13,14]. Additionally, we now find both
current smoking and number of pack-years to predict
decreased immune response within this group after adjust-
ment for demographic and relevant disease characteristics.
In contrast to smoking, alcohol consumption was asso-
ciated with lower levels of CRP and ESR in the entire
study population. The vast majority of patients participat-
ing in this study reported low to moderate alcohol con-
sumption with median weekly consumption of 71 g. Our
results are in line with other reports on anti-inflamma-
tory and cardioprotective effects of moderate alcohol
consumption [11,12,17].
In summary, in the present study we confirm that
smoking can influence immune response. The most pro-
nounced effect was seen in RA patients treated with
MTX as monotherapy where smoking was identified as a
predictor of diminished immune response following
pneumococcal vaccination. Both smoking and alcohol
consumption had an impact on systemic inflammation:
smoking being associated with higher and alcohol with
lower level of inflammatory markers. Our results contri-
bute to the growing evidence of negative effects of smok-
ing and possible advantages of moderate alcohol drinking
in patients with established arthritis.
Conclusions
Smoking predicted impaired immune response to pneu-
mococcal conjugate vaccine in RA patients on MTX.
Smokers with arthritis had higher inflammatory markers
and lower IgG regardless of diagnosis and treatment.
Low to moderate alcohol consumption was related to
lower levels of inflammation markers but had no impact
on immune response.
Abbreviations
CRP: C-reactive protein; DMARDs: disease modifying anti-rheumatic drugs;
ESR: erythrocyte sedimentation levels; GMC: geometric mean concentration;
Ig: immunoglobulin levels; IR: immune response; MTX: methotrexate; NSAIDS:
nonsteroidal anti-inflammatory drugs; posIR: positive immune response; RA:
rheumatoid arthritis; SJC: swollen joint count; SpA: spondylarthropathy; TJC:
tender joint count; TNF: tumour necrosis factor.
Acknowledgements
The authors thank the late research nurse Lotta Larsson for her professional
and meticulous monitoring of this study. We thank nurses Elna Haglund,
Eva-Karin Kristoffersson, Helen Axelsson and Kathe Nilsson for their help with
vaccination, collecting the blood samples and carrying out the study, as well
as Peter Kapral, Maria Jacobsson, Ingrid Moberg, Ingrid Bondesson, Ingrid
Hermansson and Eva Hommerberg at the Skånes Universitetssjukhus Lund
and Malmö, Department of Rheumatology for taking care of blood samples,
and Ingrid Mattsson-Geborek for her skillful help with figures. We thank all
patients for their participation in the study and all colleagues for their
cooperation and support during the study.
The study is supported by grants from the Swedish Rheumatism Association,
the Swedish Research Council, the Medical Faculty of Lund University, the
Alfred Österlund Foundation, the Crafoord Foundation, the Greta and Johan
Kock Foundation, King Gustaf V’s 80-YearFoundation, and Lund University
Hospital.
Prevenar vaccine for this study was provided by Whyeth Pharmaceuticals.
Author details
1Department of Clinical Sciences, Section of Rheumatology, Lund University,
Kioskgatan 3, Lund SE-221 85, Sweden. 2Department of Laboratory Medicine,
Section of Microbiology, Immunology and Glycobiology, Lund University,
Lund SE-221 85, Sweden.
Authors’ contributions
CR participated in the design of the study, performed the statistical analysis
and prepared the manuscript. LT and MCK conceived of the study,
participated in its design and coordination, and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 May 2012 Revised: 2 July 2012 Accepted: 23 July 2012
Published: 23 July 2012
References
1. Centers for Disease Control and Prevention (CDC); Advisory Committee on
Immunization Practices: Updated recommendations for prevention of
invasive pneumococcal disease among adults using the 23-valent
Roseman et al. Arthritis Research & Therapy 2012, 14:R170
http://arthritis-research.com/content/14/4/R170
Page 7 of 8
pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly
Rep 2010, 59:1102-1106.
2. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS,
Breiman RF: Cigarette smoking and invasive pneumococcal disease.
Active Bacterial Core Surveillance Team. N Engl J Med 2000, 342:681-689.
3. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J,
Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A,
Padyukov L, Alfredsson L: A new model for an etiology of rheumatoid
arthritis: smoking may trigger HLA-DR (shared epitope)-restricted
immune reactions to autoantigens modified by citrullination. Arthritis
Rheum 2006, 54:38-46.
4. Sankilampi U, Isoaho R, Bloigu A, Kivelä SL, Leinonen M: Effect of age, sex
and smoking habits on pneumococcal antibodies in an elderly
population. Int J Epidemiol 1997, 26:420-427.
5. Moszczyński P, Zabiński Z, Moszczyński P Jr, Rutowski J, Słowiński S,
Tabarowski Z: Immunological findings in cigarette smokers. Toxicol Lett
2001, 118:121-127.
6. Cruijff M, Thijs C, Govaert T, Aretz K, Dinant GJ, Knottnerus A: The effect of
smoking on influenza, influenza vaccination efficacy and on the
antibody response to influenza vaccination. Vaccine 1999, 17:426-432.
7. Domagala-Kulawik J: Effects of cigarette smoke on the lung and systemic
immunity. J Physiol Pharmacol 2008, 59:19-34.
8. Holt PG: Immune and inflammatory function in cigarette smokers. Thorax
1987, 42:241-249.
9. Díaz LE, Montero A, González-Gross M, Vallejo AI, Romeo J, Marcos A:
Influence of alcohol consumption on immunological status: a review. Eur
J Clin Nutr 2002, 56:S50-S53.
10. Zahs A, Cook RT, Waldschimdt TJ, Choudhry MA, Kovacs EJ, Bird MD:
Alcohol and inflammation and infection: clinical and experimental
systems-summary of the 2010 Alcohol and Immunology Research
Interest Group Meeting. Alcohol 2012, 46:147-153.
11. Romeo J, Wärnberg J, Nova E, Díaz LE, Gómez-Martinez S, Marcos A:
Moderate alcohol consumption and the immune system: a review. Br J
Nutr 2007, 98:S111-S115.
12. Estruch R, Sacanella E, Badia E, Antúnez E, Nicolás JM, Fernández-Solá J,
Rotilio D, de Gaetano G, Rubin E, Urbano-Márquez A: Different effects of
red wine and gin consumption on inflammatory biomarkers of
atherosclerosis: a prospective randomized crossover trial. Effects of wine
on inflammatory markers. Atherosclerosis 2004, 175:117-123.
13. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P:
Influence of methotrexate, TNF-blocker and prednisolone on antibody
responses to pneumococcal polysacharide vaccine in patients with
rheumatoid arthritis. Rheumatology 2006, 45:106-111.
14. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P:
Antibody response is reduced following vaccination with 7-valent
conjugate pneumococcal vaccine in adult methotrexate-treated patients
with established arthritis, but not those treated with tumour necrosis
factor inhibitors. Arthritis Rheum 2011, 63:723-732.
15. WHO: Training manual for Streptococcus pneumoniae serotype specific
IgG (PN PS ELISA)., Available at:[http://www.vaccine.uab.edu].
16. Giovannucci E, Colditz G, Stampfer MJ, Rimm EB, Litin L, Sampson L,
Willett WC: The assessment of alcohol consumption by a simple self-
administered questionnaire. Am J Epidemiol 1991, 133:810-817.
17. Pai JK, Mukamal KJ, Rimm EB: Long-term alcohol consumption in relation
to all-cause and cardiovascular mortality among survivors of myocardial
infarction: the Health Professionals Follow-up Study. Eur Heart J 2012,
33:1598-1605.
18. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF:
Systemic effects of smoking. Chest 2007, 131:1557-1566.
19. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P,
Gallimore JR, Pepys MB: Low grade inflammation and coronary heart
disease: prospective study and updated meta-analyses. BMJ 2000,
321:199-204.
20. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G,
Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein
concentration and risk of coronary heart disease, stroke, and mortality:
an individual participant meta-analysis. Lancet 2010, 375:132-140.
21. Chan ES, Cronstein BN: Methotrexate–how does it really work? Nat Rev
Rheumatol 2010, 6:175-178.
22. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X,
Combe B, Dougados M, Mariette X, Taoufik Y: Blood memory B cells are
disturbed and predict the response to rituximab in patients with
rheumatoid arthritis. Arthritis Rheum 2011, 63:3692-3701.
23. Forey B, Lee P: Estimation of sex-specific smoking statistics by
standardized age groups and time periods. In International Smoking
Statistics. A Collection of Historical Data from 30 Economically Developed
Countries. Edited by: Forey B, Hamling J, Lee P, Wald N. London and Oxford:
Wolfson Institute of Preventative Medicine and Oxford University Press;
2002:1-201.
24. Henriques Normark B, Kalin M, Ortqvist A, Akerlund T, Liljequist BO,
Hedlund J, Svenson SB, Zhou J, Spratt BG, Normark S, Källenius G:
Dynamics of penicillin-susceptible clones in invasive pneumococcal
disease. J Infect Dis 2001, 184:861-869.
doi:10.1186/ar3923
Cite this article as: Roseman et al.: The effect of smoking and alcohol
consumption on markers of systemic inflammation, immunoglobulin
levels and immune response following pneumococcal vaccination in
patients with arthritis. Arthritis Research & Therapy 2012 14:R170.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Roseman et al. Arthritis Research & Therapy 2012, 14:R170
http://arthritis-research.com/content/14/4/R170
Page 8 of 8
